Cargando…

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

BACKGROUND: During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challenges. We present a case study of a prospective–ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484825/ https://www.ncbi.nlm.nih.gov/pubmed/26137564 http://dx.doi.org/10.1016/j.ebiom.2015.02.005

Ejemplares similares

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
por: Wakui, Hiroshi, et al.
Publicado: (2014)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
por: Jänne, Pasi A., et al.
Publicado: (2022)

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
por: Lu, Yasong, et al.
Publicado: (2022)

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2016)

Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
Publicado: (2022)

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2021)

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
por: Shimizu, Toshio, et al.
Publicado: (2017)

Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Cancer Tissue
por: Kristof, Jessica, et al.
Publicado: (2017)

An Essential Role for Nuclear Factor κB in Promoting Double Positive Thymocyte Apoptosis
por: Hettmann, Thore, et al.
Publicado: (1999)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors
por: Gan, Hui K., et al.
Publicado: (2021)

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation
por: Hettmann, Thore, et al.
Publicado: (2020)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma
por: Asano, Teizo, et al.
Publicado: (2021)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
por: Osada, Takuya, et al.
Publicado: (2018)

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers
por: Okita, Kouki, et al.
Publicado: (2020)

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors
por: Saba, Nabil F., et al.
Publicado: (2012)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
por: Chang, Yi-Fang, et al.
Publicado: (2019)

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
por: Goto, Koichi, et al.
Publicado: (2023)

Epidermal stem cell dynamics
por: Sieber-Blum, Maya
Publicado: (2011)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Clinical development of immunotherapies for HER2(+) breast cancer: a review of HER2-directed monoclonal antibodies and beyond
por: Costa, Ricardo L. B., et al.
Publicado: (2020)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
por: Denlinger, Crystal S., et al.
Publicado: (2021)

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer
por: Zhang, Shu, et al.
Publicado: (2016)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment
por: Akinnusi, Precious A, et al.
Publicado: (2022)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Regulation of ERBB3/HER3 signaling in cancer
por: Mujoo, Kalpana, et al.
Publicado: (2014)

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
por: Sarkis, Julien, et al.
Publicado: (2020)

HER-3: hub for escape mechanisms
por: Capone, Emily, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1m7ifis1ja2e90pc5hhle27tos